Related Experiment Videos
The antiarrhythmic drug BRL-32872
Christoph A Karle1, Dierk Thomas, Johann Kiehn
1Department of Cardiology, Medical University Hospital Heidelberg, Heidelberg, Germany.
Cardiovascular Drug Reviews
|August 15, 2002
Summary
BRL-32872, a novel antiarrhythmic drug, effectively treats ventricular arrhythmias in animal models by blocking potassium and calcium channels. Its unique "bell-shaped" action profile may prevent dangerous side effects like torsades de pointes.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
- Molecular Biology
Background:
- BRL-32872 is a novel antiarrhythmic agent.
- It exhibits balanced Vaughan-Williams Class-III and Class-IV actions.
- Its mechanism involves blocking cardiac ion channels.
Purpose of the Study:
- To characterize the electrophysiological properties of BRL-32872.
- To investigate its potential to prevent proarrhythmic effects.
- To evaluate its efficacy in animal models of cardiac ischemia.
Main Methods:
- In vitro electrophysiology to assess channel blockade (IK(r), HERG, ICa).
- In vivo studies in animal models of cardiac ischemia.
- Analysis of action potential duration and QTc interval.
Main Results:
- BRL-32872 blocks IK(r) and HERG channels at low concentrations (nM range).
- It inhibits L-type calcium current (ICa) at higher concentrations (µM range).
- Demonstrated efficacy in reducing ventricular arrhythmias and early afterdepolarizations in ischemic animal hearts.
Conclusions:
- BRL-32872 possesses a concentration-dependent dual action profile.
- This profile may prevent excessive QTc prolongation and torsades de pointes.
- The drug shows significant antiarrhythmic effects in preclinical models of cardiac ischemia.